Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Lipids: Dietary Sources and Requirements01:18

Lipids: Dietary Sources and Requirements

Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ meats, shellfish,...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparative efficacy and safety of olezarsen versus volanesorsen for familial chylomicronemia syndrome: a matching-adjusted indirect comparison.

Journal of comparative effectiveness research·2026
Same author

Exploring the material basis and potential mechanism of spleen-strengthening and damp-resolving prescriptions in the treatment of diabetes mellitus complicated with obesity based on data mining, UPLC-Q-TOF-MS/MS and network pharmacology.

Naunyn-Schmiedeberg's archives of pharmacology·2026
Same author

Exposure to Antibiotics Modifies the Immune Profiles of Bacterial Extracellular Vesicles from Common Vaginal Anaerobes.

bioRxiv : the preprint server for biology·2026
Same author

In Vivo Base Editing of <i>PCSK9</i> with VERVE-102 for Hypercholesterolemia.

The New England journal of medicine·2026
Same author

Global survey of genetic testing methods for familial hypercholesterolemia. A study and recommendations from the EAS FHSC registry.

European journal of preventive cardiology·2026
Same author

Interrelationship Between Socioeconomic Status, Depression, and Neuropathy in People with Diabetes: A Cross-Sectional Study.

Journal of clinical medicine·2026

Related Experiment Video

Updated: May 10, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

High-density lipoprotein cholesterol raising: does it matter?

Jonathan D Schofield1, Michael France, Basil Ammori

  • 1Cardiovascular Trials Unit, Central Manchester University Hospitals, Manchester, UK.

Current Opinion in Cardiology
|June 6, 2013
PubMed
Summary
This summary is machine-generated.

Raising high-density lipoprotein cholesterol (HDL-C) levels may not improve cardiovascular outcomes. Future therapies should focus on HDL functionality, not just cholesterol levels, for better heart health.

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Related Experiment Videos

Last Updated: May 10, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Area of Science:

  • Cardiology
  • Biochemistry
  • Public Health

Background:

  • Cardiovascular disease (CVD) is a major global health concern, with high-density lipoprotein cholesterol (HDL-C) recognized as a key predictor of cardiovascular events.
  • Low HDL-C levels pose a residual risk, even in patients with controlled low-density lipoprotein cholesterol (LDL-C).
  • Previous research suggested raising HDL-C as a potential therapeutic strategy due to strong epidemiological and biological evidence.

Purpose of the Study:

  • To evaluate the effectiveness of HDL-C raising therapies in improving cardiovascular outcomes.
  • To examine the role of HDL-C levels versus HDL functionality in cardiovascular risk.
  • To inform future therapeutic strategies for managing cardiovascular disease.

Main Methods:

  • Analysis of three large randomized clinical trials.
  • Investigation of HDL-C raising agents (niacin and dalcetrapib) in statin-treated patients.
  • Assessment of cardiovascular outcomes in relation to HDL-C levels and therapeutic interventions.

Main Results:

  • Recent large-scale clinical trials failed to show improved cardiovascular outcomes with HDL-C raising agents like niacin and dalcetrapib.
  • These findings challenge the previous assumption that simply increasing HDL-C levels is beneficial.
  • The results suggest that the effectiveness of HDL-C interventions may depend on factors beyond plasma concentration.

Conclusions:

  • HDL functionality, rather than plasma HDL-C levels, appears to be more critical for cardioprotection.
  • Future therapeutic approaches should aim to enhance HDL functionality.
  • Developing agents that improve HDL's biological activity is crucial for effective CVD management.